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Hemoglobin levels and the dose of erythropoiesis-
stimulating agents (ESAs) have risen over time in
hemodialysis patients within the United States. There are
concerns that these trends may be driven by reimbursement
policies that provide potential incentives to increase this use.
To determine this we studied trends in the use of ESA and
hemoglobin levels in hemodialysis patients and the
relationship of these trends to the mode of reimbursement.
Using the Dialysis Outcomes and Practice Patterns Study
(DOPPS) database of hemodialysis we analyzed facility
practices in over 300 randomly selected dialysis units in
12 countries. At each of three phases (years 1996–2001,
2002–2004, and 2005–present), we randomly selected over
7500 prevalent hemodialysis, hemofiltration, or
hemodiafiltration patients. ESA usage rose significantly in
every country studied except Belgium. All but Sweden
demonstrated a substantial increase in hemoglobin levels. In
2005 more than 40% of patients had hemoglobin levels
above the KDOQI upper target limit of 120g/l in all but
Japan. These trends appeared to be independent of the
manner of reimbursement even though the United States is
the only country with significant financial incentives promoting
increased use of these agents. Thus, our study found that
prescribing higher doses of ESAs and achieving higher
hemoglobin levels by physicians reflects a broad trend across
DOPPS countries regardless of the reimbursement policies.
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Anemia is common in end-stage renal disease. About 90% of
hemodialysis patients in the US now receive an erythropoi-
esis-stimulating agent (ESA) such as erythropoietin-a (EPO-
a) (EPO-a—Epogen, Amgen, Thousand Oaks, CA, USA;
Eprex or Procrit, Ortho-Biotech, Bridgewater, NJ, USA) or
darbepoetin-a (Aranesp; Amgen, Thousand Oaks, CA,
USA).1 In European countries, EPO-b (Recormon; Roche,
Basel, Switzerland) is also commonly used. Hemoglobin
levels and ESA dose have risen over time among US
hemodialysis patients, half of whom now have a hemoglobin
level above the 1997 and 2001 Kidney Disease Outcomes
Quality Initiative (KDOQI) target range upper limit of
120 g/l.2–4 Recent studies have questioned the safety of
achieving high hemoglobin levels with ESAs, prompting the
US Food and Drug Administration to issue ‘black box’
warnings recommending against hemoglobin levels greater
than 120 g/l in dialysis patients.5 This has led to speculation
regarding the drivers of these trends. One candidate has been
the previous reimbursement policies of the Centers for
Medicare & Medicaid Services (CMS) in the US, which may
have favored higher ESA doses.2 Examining whether these
trends exist in other jurisdictions with different ESA funding
would help inform this debate.
The Dialysis Outcomes and Practice Patterns Study
(DOPPS) database can be used to examine international
differences in anemia practice. The DOPPS is a prospective
observational study investigating associations between he-
modialysis facility practices and patient outcomes over three
phases of longitudinal data collection.6 DOPPS I (1996–2001)
collected data from the US, France, Germany, Italy, Japan,
Spain, and the UK. DOPPS II and III (2002–2004 and
2005–2008) also included Australia, Belgium, Canada, New
Zealand, and Sweden.
We hypothesized that trends toward higher hemoglobin
values and increased ESA use would be seen in hemodialysis
patients in all DOPPS countries, independent of the form of
ESA reimbursement. We examined the period leading up to
changes in CMS policy in the US in 2007.
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RESULTS
The study population included 7435 patients in DOPPS I,
8409 in DOPPS II, and 7789 in DOPPS III (Table 1;
additional characteristics available in the online Appendix).
Patients from Japan, France, and Italy had been on dialysis
significantly longer. Body mass index was significantly
lower in Japan and significantly higher in the US. More
patients in Canada and the US had diabetes. Average patient
age increased over DOPPS phases except in Canada,
Sweden, and the UK. Average body mass index and the
proportion of patients with diabetes increased in all DOPPS
countries over time, statistically significantly so in half of the
countries.
Hemoglobin levels increased significantly in all DOPPS
countries except Sweden (Table 2 and Figure 1) where
patients had the highest average hemoglobin levels in
DOPPS II. The proportion of patients with a hemoglobin
level above 120 g/l also rose significantly with two exceptions
(Table 2); this trend was not statistically significant in
Canada, and there was no increase in Sweden, which had the
highest proportion above 120 g/l in DOPPS II.
ESA doses increased significantly in all DOPPS countries
except Belgium (Table 3 and Figure 1) and remained
significant after adjusting for covariates. The increase in
ESA dose from DOPPS I to III ranged from 9.6% (Japan) to
106.6% (France). ESA doses and the percentage of patients
with a weekly ESA dose 435,000 U/week were highest in
the US (Table 4). However, six countries had higher
percentage increases in ESA dose between DOPPS II and III
than the US (ANZ, Canada, France, Italy, Spain, and the UK);
other countries had comparable increases (Germany and
Sweden).
Table 1 | Selected demographic parameters among countries participating in the DOPPS study
Phase ANZa BEa CAa FRa GEa ITa JAa SPa SWa UKa USa
nb
I NAc NAc NAc 581 597 581 2122 523 NAc 457 2574
II 476 485 557 487 536 525 1674 581 511 517 2060
III 463 474 488 505 553 506 1748 528 505 340 1679
Age (years)
I NAc NAc NAc 60.1±0.7 60.3±0.6 61.9±0.6 58.3±0.3 61.0±0.7 NAc 57.7±0.8 59.7±0.3
II 60.4±0.7 66.6±0.6 62.2±0.7 64.8±0.7 61.5±0.6 64.2±0.6 60.4±0.4 62.8±0.7 63.3±0.7 60.8±0.8 61.3±0.4
III 62.5±0.7 69.1±0.6 61.6±0.8 64.9±0.7 62.5±0.6 64.4±0.6 62.0±0.3 63.8±0.7 65.1±0.7 60.1±1.0 61.8±0.4
Pd 0.02 o0.01 0.57 o0.01 0.01 o0.01 o0.01 o0.01 0.06 0.06 o0.01
% Taking ESA
I NAc NAc NAc 71.3 71.7 83.7 81.0 88.6 NAc 87.7 92.4
II 85.9 95.5 90.7 84.1 86.8 87.7 80.0 92.4 94.9 93.0 90.6
III 90.7 93.9 93.3 92.1 86.1 85.8 82.6 94.2 94.1 90.7 91.2
Pd 0.03 0.31 0.18 o0.01 o0.01 0.35 0.32 o0.01 0.62 0.22 0.11
BMI
I NAc NAc NAc 23.8±0.2 24.9±0.2 23.6±0.2 20.5±0.1 24.2±0.2 NAc 24.6±0.3 26.0±0.2
II 25.5±0.3 24.9±0.2 25.5±0.3 24.2±0.2 25.1±0.2 24.3±0.2 20.5±0.1 24.8±0.2 24.5±0.2 25.0±0.3 26.8±0.2
III 27.1±0.3 25.2±0.3 26.2±0.4 24.2±0.2 26.1±0.2 24.2±0.2 20.9±0.1 24.9±0.2 25.2±0.3 25.1±0.3 27.6±0.2
Pd o0.01 0.44 0.11 0.37 o0.01 0.03 o0.01 0.04 0.05 0.26 o0.01
Time on hemodialysis (years)
I NAc NAc NAc 6.5±0.3 4.1±0.2 6.1±0.3 8.0±0.2 5.0±0.3 NAc 4.2±0.2 4.0±0.1
II 4.9±0.3 4.0±0.2 4.8±0.3 6.4±0.4 4.4±0.2 6.3±0.3 7.8±0.2 4.9±0.2 4.1±0.2 4.5±0.3 3.6±0.1
III 5.3±0.3 3.8±0.2 4.8±0.3 6.2±0.3 4.7±0.2 6.8±0.4 8.7±0.2 4.8±0.3 4.4±0.2 5.2±0.3 3.9±0.1
Pd 0.28 0.46 0.93 0.43 0.04 0.11 o0.01 0.64 0.37 0.01 0.4
Percentage of patients with diabetes
I NAc NAc NAc 17.9 30.3 15.1 25.1 23.7 NAc 16.1 48
II 34.6 30.0 40.2 21.5 30.7 17.6 26.8 26.1 33.6 22.0 51.8
III 41.8 35.2 45.6 27.0 37.4 22.3 31.5 30.1 37.4 26.1 55.4
Pd 0.03 0.10 0.14 o0.01 0.02 o0.01 o0.01 0.03 0.25 o0.01 o0.01
% Black
I NAc NAc NAc 2.3 0.3 0.1 0.0 0.5 NAc 6.8 39.4
II 0.2 3.7 6.7 5.3 0.0 0.2 0.0 0.2 0.8 4.5 34.2
III 1.0 3.0 6.5 2.9 0.6 0.8 0.0 1.5 0.6 6.2 37.0
Pd 0.18 0.57 0.90 0.62 0.41 0.11 NA 0.14 0.77 0.77 0.08
Abbreviations: BMI, body mass index; DOPPS, Dialysis Outcomes and Practice Patterns Study; ESA, erythropoiesis-stimulating agent.
aANZ, Australia/New Zealand; BE, Belgium; CA, Canada; FR, France; GE, Germany; IT, Italy; JA, Japan; SP, Spain; SW, Sweden; UK, United Kingdom; US, United States.
bIncluding patients with some missing data.
cNot applicable: Country did not participate in DOPPS I.
dLevel of significance for linear trend within country across DOPPS phases.
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Intravenous (IV) iron dose rose significantly in four
countries (Canada, France, Italy, and Sweden) and fell
significantly in the US (Table 5). Country-level changes in
hemoglobin level were not significantly correlated with
changes in iron dose. Patient-level iron doses did not
significantly affect the association between ESA dose and
phase in any country.
Sensitivity analyses
The results were unchanged in sensitivity analyses, with the
following exceptions. In Japan and Sweden, the increase in
ESA dose was statistically insignificant in the multivariable
models only when facility-clustering effects were considered,
suggesting that the increases in dose were concentrated in
certain facilities. ESA trends in Germany and the UK were no
longer significant when darbepoetin doses were converted to
an equivalent IV EPO dose using a 200:1 conversion ratio
after adjusting for the 21 covariates and facility clustering, or
in Germany when using the 250:1 ratio.
For the achieved hemoglobin level, all trends were the
same whether examining means or medians, except in
Canada where the mean trend was statistically significant,
but not the median. For ESA dose, all trends were the same
whether examining means or medians, except in Belgium,
Table 2 | Trends in mean hemoglobin levels and percentage of patients with a hemoglobin level above 12.0 g/dl between the
DOPPS study phases by participating country
Hemoglobin±s.e. (g/l)a % of patients with Hg X120g/l
DOPPS phase DOPPS phase
Country I II III P-valueb I II III P-valueb
ANZc NAd 115±0.81 119±0.70 o0.001 NAd 40.0% 50.6% 0.0016
Belgium NAd 116±0.67 119±0.64 0.0009 NAd 41.7% 52.1% 0.0024
Canada NAd 116±0.70 118±0.70 0.0418 NAd 44.2% 47.9% 0.3343
France 109±0.66 113±0.88 118±0.65 o0.001 21.9% 31.3% 45.0% o0.001
Germany 108±0.64 115±0.59 117±0.62 o0.001 17.6% 33.6% 46.1% o0.001
Italy 108±0.83 114±0.75 116±0.72 o0.001 24.2% 36.2% 40.0% o0.001
Japan 97±0.33 101±0.33 105±0.32 o0.001 5.4% 7.6% 9.5% o0.001
Spain 113±0.77 118±0.69 120±0.66 o0.001 33.8% 47.4% 52.3% o0.001
Sweden NAd 120±0.67 120±0.65 0.9256 NAd 51.8% 48.7% 0.3496
UKc 107±0.87 112±0.83 117±0.98 o0.001 22.0% 32.3% 46.2% o0.001
USc 114±0.33 118±0.38 120±0.37 o0.001 36.7% 45.4% 52.0% o0.001
Abbreviations: DOPPS, Dialysis Outcomes and Practice Patterns Study; Hg, hemoglobin.
aMean hemoglobin±standard error of the mean in g/l.
bLevel of significance for linear trend within country, across DOPPS phases.
cANZ, Australia/New Zealand; UK, United Kingdom; US, United States.
dNot applicable: This country did not participate in DOPPS I.
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Figure 1 |Mean ESA dose (in IV erythropoietin equivalent units per week) and hemoglobin level in DOPPS I, II, and III by
participating country.
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where the median trend was statistically significant but not
the mean, and Japan, where the mean trend was statistically
significant but not the median (Table 6).
Public reimbursement of ESAs
ESA use was publicly funded in all DOPPS countries,
although policies varied between and within the countries.
All DOPPS countries except France and Spain placed
reimbursement restrictions on ESA initiation, requiring a
threshold degree of anemia or anemia-related symptoms. No
clear relationship between these restrictions and ESA trends
could be found, as France had the highest percent rise in ESA
usage, but only an average absolute rise in dose, and Spain
was average in both absolute and percent ESA rises. Once
initiated, ESA reimbursement was often limited to a
maximum dose, which ranged from 9000 U/week in Japan
(which had the least rise in ESA use) to 500,000 U/month in
the US. Payment restrictions also existed for high levels of
achieved hemoglobin, for example, a 3-month mean
hematocrit 437.5% in the US. As these restrictions often
varied by region within countries and over time, it is difficult
to generalize by country. We identified no incentives arising
from the type of ESA used, the dose administered, or the
achieved hemoglobin except perhaps in the US, where in
2006 public ESA reimbursement was set at 80% of the
average sales price plus 6%.7,8 Despite this, the US had the
fourth lowest absolute rise and third lowest percent rise in
ESA usage. A previous analysis also found no link between
the form of funding and patient outcomes.9
Table 3 | Trends in mean ESA dose between the DOPPS study phases by participating country
ESA dose±s.e. (U/week)a Percent ESA dose change Absolute ESA dose change (U/week)a
DOPPS phase DOPPS phase DOPPS phase
Country I II III P-valueb I to II II to III I to III I to II II to III I to III
ANZc NAd 10,001±442 16,015±875 o0.001 NAd 60.1% NAd NAd 6014 NAd
Belgium NAd 13,443±570 14,067±560 0.4356 NAd 4.7% NAd NAd 628 NAd
Canada NAd 12,233±569 18,166±1367 o0.001 NAd 48.5% NAd NAd 5933 NAd
France 6656±214 9056±337 13,702±656 o0.001 36.1% 51.8% 106.6% 2400 4694 7094
Germany 6698±338 7381±295 9488±385 o0.001 10.2% 28.4% 41.5% 683 2099 2782
Italy 8390±262 9886±401 16,232±683 o0.001 17.8% 64.3% 93.6% 1496 6357 7853
Japan 4807±70 5330±107 5266±80 o0.001 10.9% -1.1% 9.6% 523 60 463
Spain 8310±272 8735±314 13,725±512 o0.001 5.1% 57.1% 65.2% 425 4990 5415
Sweden NAd 15,304±535 19,975±888 o0.001 NAd 30.5% NAd NAd 4671 NAd
UKc 8422±401 10,055±456 15,545±957 o0.001 19.4% 55.4% 85.5% 1633 5568 7201
USc 15,959±294 17,137±512 21,386±710 o0.001 7.4% 25.0% 34.2% 1178 4283 5461
Abbreviations: DOPPS, Dialysis Outcomes and Practice Patterns Study; ESA, erythropoiesis-stimulating agent.
aMean dose of erythropoietin (EPO) or darbepoietin in intravenous EPO equivalent units/week.
bLevel of significance for linear trend within country, across DOPPS phases.
cANZ, Australia/New Zealand; UK, United Kingdom; US, United States.
dNot applicable: This country did not participate in DOPPS I.
Table 4 | Trends in percentage of patients with a mean ESA
dose greater than 35,000U/week between the DOPPS study
phases by participating country
ESA 435,000U/weeka (%)
DOPPS phase
Country I II III P-valueb
ANZc NAd 0.7% 3.8% 0.01
Belgium NAd 4.2% 3.1% 0.44
Canada NAd 2.1% 11.3% o0.001
France 0.0% 0.5% 5.6% o0.001
Germany 1.4% 0.6% 1.8% 0.61
Italy 0.0% 0.9% 6.5% o0.001
Japan 0.0% 0.0% 0.0% 0.14
Spain 0.3% 0.6% 4.0% o0.001
Sweden NAd 5.0% 12.7% o0.001
UKc 0.7% 1.3% 6.6% 0.001
USc 9.1% 10.1% 18.1% o0.001
Abbreviations: DOPPS, Dialysis Outcomes and Practice Patterns Study; ESA,
erythropoiesis-stimulating agent.
aMean dose of erythropoietin (EPO) or darbepoietin in intravenous EPO equivalent
units/week.
bLevel of significance for linear trend within country, across DOPPS phases.
cANZ, Australia/New Zealand; UK, United Kingdom; US, United States.
dNot applicable: This country did not participate in DOPPS I.
Table 5 | Trends in mean monthly intravenous iron dose,
across DOPPS phases by participating country
Mean intravenous iron dose (mg/month)
DOPPS phase
Country I II III P-valuea
ANZb NAc 193±9 185±8 0.53
Belgium NAc 262±9 250±8 0.32
Canada NAc 210±9 261±14 0.002
France 199±7 221±11 308±16 o0.001
Germany 257±7 245±8 251±10 0.61
Italy 218±12 228±12 273±16 0.005
Japan NA NA 99±4 NA
Spain 190±7 229±10 187±9 0.83
Sweden NAc 270±9 403±17 o0.001
UKb 214±10 233±12 259±16 0.016
USb 276±7 247±6 227±5 o0.001
Abbreviations: DOPPS, Dialysis Outcomes and Practice Patterns Study; NA, not
available.
aLevel of significance for linear trend within country, across DOPPS phases.
bANZ, Australia/New Zealand; UK, United Kingdom; US, United States.
cNot applicable: This country did not participate in DOPPS I.
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A variety of disincentives to escalating ESA use were
identified. In Germany, ESA use greater than that of peer
units could lead to retroactive denial of payment, and
Germany had the third lowest absolute rise and fourth lowest
percent rise in ESA usage. In parts of Canada, Italy, and more
recently in Japan and Spain, ESA costs were included in
global funding for dialysis, such that increasing ESA use
would reduce funds available for other elements of care. No
clear relationship between funding method and ESA trends
could be found; Italy had among the highest increases in ESA
use, Japan the lowest, and Canada and Spain near the overall
average. In parts of Canada, Sweden, and the US, some
patients were required to pay for a portion of their ESA use.
Again, no clear relationship between co-payment and ESA
trends could be seen. As of 2006, the US introduced a 25%
funding penalty for patients whose hemoglobin exceeded
130 g/l for three consecutive months and had not undergone
a 25% reduction in ESA dose. In other countries we could
not identify prevailing direct financial incentives or disin-
centives related to ESA use.
The DOPPS survey response rate was 90.5%. Few sites felt
that drug companies had contributed substantially to anemia
management protocols, except Canada where a quarter of
respondents identified such an influence (Table 7). No
relationship could be established between the response to this
question and trends in ESA use. Canada’s percentage increase
in ESA dose was sixth highest, and had the third highest
absolute increase (Table 3). No respondent from Italy, UK, or
Sweden answered positively, and these countries had the
second, third, and seventh largest percent increase and first,
fourth, and seventh largest absolute increase in ESA dose,
respectively. This survey also indicated that physicians and
unit medical directors could not directly financially benefit
from achieving anemia performance targets (Table 7). The
Table 6 | Trends in median hemoglobin levels and median ESA dose between the DOPPS study phases by participating country
Hemoglobin (g/l)a ESA dose (U/week)c
DOPPS phase DOPPS phase
Country I II III P-valueb I II III P-valueb
ANZd NAe 115 (103–126) 119 (109–130) 0.003 NAe 9200(600–13,800) 12,500 (8000–20,000) o0.001
Belgium NAe 116 (106–124) 120 (112–127) o0.001 NAe 10,500 (6325–16,500) 12,000 (6750–18,000) 0.036
Canada NAe 117 (107–125) 118 (109–125) 0.076 NAe 9200 (5175–16,100) 13,200 (8000–20,000) o0.001
France 109 (97–117) 113 (103–123) 118 (108–126) o0.001 6000 (3450–9200) 7475 (4950–11,500) 9900 (6000–16,500) o0.001
Germany 107 (98–116) 114 (106–123) 118 (108–126) o0.001 6000 (3000–8000) 6000 (4000–9900) 7200 (4000–12,000) o0.001
Italy 107 (96–119) 114 (103–123) 115 (106–124) o0.001 6900 (4600–11,500) 8000 (4600–13,800) 12,000 (6600–21,900) o0.001
Japan 96 (88–105) 100 (93–108) 104 (96–112) o0.001 4500 (3000–6000) 4750 (3000–7125) 4500 (3000–9000) 1.000
Spain 112 (102–123) 118 (107–128) 120 (111–129) o0.001 6900 (4600–10,350) 6900 (4600–12,000) 10,500 (6000–18,000) o0.001
Sweden NAe 119 (110–130) 119 (110–128) 1.000 NAe 11,500 (6900–20,700) 14,775 (9000–26,250) o0.001
UKd 108 (94–118) 113 (102–122) 117 (105–127) o0.001 6900 (4600–10,350) 7763 (4600–13,800) 10,000 (6600–19,800) o0.001
USd 115 (105–124) 118 (109–126) 120 (112–128) o0.001 12,000 (6600–22,500) 12,000 (6000–22,500) 14,000 (6725–28,500) 0.039
Abbreviations: DOPPS, Dialysis Outcomes and Practice Patterns Study; ESA, erythropoiesis-stimulating agent.
aMedian hemoglobin in g/l.
bLevel of significance for linear trend within country, across DOPPS phases.
cMedian dose of erythropoietin (EPO) or darbepoietin in intravenous EPO equivalent units/week.
dANZ, Australia/New Zealand; UK, United Kingdom; US, United States.
eNot applicable: This country did not participate in DOPPS I.
Table 7 | Answers from DOPPS III questionnaire anemia management section
Question
(1) Who substantially contributed to designing
and/or writing protocols in the area of anemia?
(2) Do any of the following entities or individuals receive
financial reward for achieving performance targets for your unit?
Country (% of facilities answering ‘Drug company’)
(% of facilities
identifying physicians)
(% of facilities identifying
medical director)
ANZa 5.0% 0% 0%
Belgium 5.6% 0% 0%
Canada 25.0% 0% 0%
France 6.7% 0% 0%
Germany 10.0% 0% 0%
Italy 0.0% 33.3% 26.7%
Japan 8.2% 0% 0%
Spain 9.5% 15.8% 10.0%
Sweden 0% 0% 0%
UKa 0% 0% 0%
USa 9.4% 0% 2.0%
Abbreviation: DOPPS, Dialysis Outcomes and Practice Patterns Study.
aANZ, Australia/New Zealand; UK, United Kingdom; US, United States.
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exceptions included Italy and Spain. Italy had the highest
absolute and second highest percent increase in ESA usage,
whereas Spain had the fifth highest absolute and fourth
highest percent increase in ESA usage.
DISCUSSION
ESA usage and hemoglobin levels in hemodialysis patients
each rose significantly in 10 of 11 DOPPS regions. No
country had a significant fall in ESA usage, hemoglobin level,
or iron utilization, indicating that the movement toward
more aggressive anemia management in US hemodialysis
patients is part of a broad international trend.
The US was the only DOPPS country with an ESA
reimbursement structure providing potential financial in-
centives for dialysis units to increase ESA use, and the average
ESA dose was highest in the US, but the increase in ESA dose
was relatively low. Japan had the most restrictive policy and
the lowest average ESA dose and hemoglobin level, and the
least increase in ESA dose. However, ESA dose, hemoglobin
levels, or both rose in all DOPPS countries regardless of ESA
reimbursement policies—including Japan and Germany
where strong disincentives (including risks to physician
income) exist against such increases, and in countries where
inclusion of EPO costs within dialysis reimbursement meant
that increased EPO use must be balanced by reduced
expenditures elsewhere. Our survey did not find any strong
linkages between the percentage of facilities identifying
financial rewards for achieving performance targets and
ESA trends, although Italy was the only country with a
relatively high positive response rate and had some of the
largest increases in ESA usage. We did not find any clear
relationships between ESA trends and whether ESA funding
was included in overall dialysis funding, nor whether patients
were required to co-pay for ESAs. Given that similar trends
have occurred in countries with a variety of reimbursement
policies, it seems likely that they are driven by more universal
factors then ESA reimbursement. While it is likely that
reimbursement contributed to these trends in the US, it is
also likely that non-reimbursement factors affect ESA usage
in the US as well.
What other potential drivers exist for these trends? One
candidate is the statistical consequence of achieving anemia
management benchmarks.10 A mean hemoglobin level of
about 121–128 g/l would be required to have a hemoglobin
4110 g/l in at least 85% of patients.11,12 Clinicians may have
increasingly favored higher hemoglobin levels, perhaps
influenced by international guideline groups,4,10,13–21 or
research reports.1,22,23 Figure 2 lists the recommended targets,
but excludes many of the caveats that these guidelines discuss
in their text. For example, in Australia/New Zealand no
difference in hemoglobin levels were seen in dialysis patients
with or without cardiovascular disease between 2004 and
2006 despite differing CARI recommendations for these
groups.
Guideline
group
DOQI/
K/DOQI1 11.0–12.0 11.0–12.0 11.0–13.0
11.0-12.0
≥ 10.0 10.5–12.5
CSN2
CARI3
UK-RA/
NCC-CC/NICE4
EBPG5
DOPPS I
1 - Dialysis Outcomes Quality Initiative/Kidney Disease Outcomes Quality Initiative
2 - Canadian Society of Nephrology
3 - Caring for Australasians with Renal Impairment
4 - United Kingdom — The Renal Association/National Collaborating Centre for Chronic
Conditions/National Institute for Health and Clinical Excellence
5 - European Best Practice Guidelines
DM = diabetes, CVD = cardiovascular disease
>11.0
11.0 –12.0 DM/CVD
11.0–12.0 CVD
12.0–14.0 no CVD
≥11.0, 11.0 – 12.0 CVD
12.0 –14.0 no CVD
>11.0
11.0 –12.0 DM/CVD
DOPPS II DOPPS III
Year of guideline release
‘97 ‘99 ‘01 ‘03 ‘05 ‘07
Figure 2 |Hemoglobin target range (in g/l) for adult hemodialysis patients on an ESA by year and by international guideline group.
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These results were not substantially altered in analyses
accounting for case mix or changes in case mix. It remains
possible that unmeasured parameters correlated with anemia
therapy outcomes may have differed between the DOPPS
phases. Our results were robust and generally insensitive to
analysis assumptions and dose conversion methods, and
consistent after adjustment for factors known to affect ESA
dose. There was no relationship between these trends and
markers of malnutrition or inflammation, suggesting that
dose increases were not due to changes in ESA sensitivity.
Similarly, changes in iron indices or iron management
practices did not explain these results. Sampling error is
unlikely to explain these findings due to the random selection
process, and estimates from the DOPPS have been shown to
be similar to census-based registry data.24,25
Despite higher ESA use, US hemoglobin levels were
similar to most other DOPPS countries, suggesting lower US
patient ESA responsiveness. In the US it was more common
to see high ESA doses, and until DOPPS III usage beyond
35,000 IV EPO-equivalent units per week was rare outside of
the US, with a ceiling ESA dose that was rarely exceeded.
The tendency toward use of very high doses in presumably
hypo-responsive patients increased across DOPPS phases.
The gap between mean and median ESA use suggests that
some of the increased ESA use was clustered in a smaller
group of patients receiving high doses, although as Table 6
suggests, outliers did not explain all of these trends as our
conclusions remain robust whether examining mean or
median usage.
When considering the role of ESA reimbursement, these
conclusions are based on survey results, previous publica-
tions, and publicly available policy documents. Inter- and
intra-country variability in ESA reimbursement, lack of
transparency in some jurisdictions, and policy changes within
the study period made capturing the nuances of ESA funding
difficult. However, it does not appear that systematic
reimbursement incentives favoring greater ESA use existed
in DOPPS countries outside of the US during the three
DOPPS phases.
Reimbursement is only one aspect of the interplay
between finances and anemia management. While our study
was not designed to examine all such interactions, we have
presented some relevant survey data, which did not find any
correlation between our results and the perceptions of drug
company influence in the development of anemia protocols.
This does not rule out an influence of industry on these
trends. Drug companies are reluctant to detail their
promotional activities, and physician recall of these activities
is prone to error. For example, industry may have influenced
these trends through educational events highlighting research
and guidelines favoring higher hemoglobin targets. Without
greater openness on industry’s part, it is unlikely that we will
be able to examine scientifically the extent to which such
activities have contributed to these trends.
Undisclosed or unmeasured financial incentives may have
contributed to increased ESA usage; however, such incentives
would have had to have been present across DOPPS
countries, and have affected clinician practice to an extent
that overcame budgetary restraints and other financial
disincentives. While financial structures (such as provider
organizational status)26 that provide incentives for increased
ESA use cannot be excluded, focus should be given to
promotion of guidelines whose hemoglobin target contains
an evidence-based upper range, and to quality-improvement
practices that assist in maintaining hemoglobin within the
target range.
The results of this study show that clinicians have
increased ESA doses and achieved higher hemoglobin levels
as part of a broad international trend. Our finding of similar
trends in other countries does not support the speculation
that this trend is a US phenomenon. Further studies are
needed to better define the factors that drive medical
decision-making and facility policy related to anemia
management in hemodialysis patients.
METHODS
Data source and study sample
The DOPPS selected a stratified random sample of over 300 dialysis
facilities representative of facility type and geographic distribution.
In each DOPPS phase, 20–40 patientsX18 years old were randomly
selected at each site. Details of the DOPPS sampling plan and
methods have been described previously.6,27 The DOPPS has been
approved and patient consent obtained as required by national and
local ethics committee regulations.
For this study, the DOPPS I sample reflects a cross-section of
patients on 1 October 1999; the DOPPS II and III samples reflect the
initial cross-section of patients in each phase. We studied those
receiving dialysis for 490 days and treated at the facility for 44
weeks, as hemoglobin rises during the first three months of
dialysis.22 Outlying doses (any EPO dose p750 U/week (n¼ 62),
or 4150,000 U/week (n¼ 3), or darbepoetin dose 4225 mcg/week
(n¼ 17)) were excluded. Demographic and comorbidity character-
istics were collected at study entry; all other data reflect the most
recent measure at each phase’s cross-section.
Changes in ESA dose and hemoglobin were examined by country
across DOPPS phases, and tested using multivariable models
adjusting for 21 covariates: age; sex; race; time on dialysis; body
mass index; vascular access type; dialysis clearance of urea (Kt/V);
serum albumin; and presence of coronary artery disease, congestive
heart failure, other cardiac disease, cancer, cerebrovascular disease,
diabetes, gastrointestinal bleeds, HIV/AIDS, hypertension, pulmon-
ary disease, neurological or psychiatric disorders, peripheral vascular
disease, and recurrent cellulitis or gangrene. Other models
additionally adjusted for iron dose. Japan was excluded from
DOPPS I and II iron analyses due to concerns about data accuracy.
Multivariable analyses were repeated adjusting ESA dose for
body weight.
IV EPO dose equivalency and sensitivity analyses
Because of increased use of Aranesp and IV EPO, models stratified
for type of ESA and delivery route were not possible.1 ESA doses
were converted to an equivalent IV EPO dose. More EPO is required
when delivered IV than subcutaneously.28–32 Subcutaneous EPO
doses were converted into an equivalent IV dose by applying a
þ 15% adjustment; sensitivity analyses used a þ 30% adjustment.10–11
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Studies suggest that IV darbepoetin is as potent as subcuta-
neous,33–35 so no such adjustments were made to darbepoetin doses
in the primary analysis, but were applied in a sensitivity analysis.
By molecular mass conversion, 200 U of EPO-a is equivalent to
1 mg of darbepoetin.36 However, analyses have proposed that less
darbepoetin is required than this ratio would suggest.34,37,38 The
product monograph for Aranesp in the US and Canada suggests a
conversion ratio ranging from 200:1 to 900:1 depending on the
original EPO dose.39,40 Darbepoetin doses were converted to an
equivalent IV EPO dose using the 330:1 conversion ratio used by
CMS,41 with sensitivity analyses performed using ratios of 200:1,
250:1, and the monograph ratios. The prevalence of having a
relatively high ESA dose, arbitrarily defined as exceeding the
equivalent of 35,000 U/week of EPO, was also examined.
Mean doses were used to better represent total ESA utilization.
Median doses were examined in a sensitivity analysis.
ESA funding
In June 2007 a questionnaire examining ESA reimbursement
practices was distributed to each country’s DOPPS investigators,
examining ESA reimbursement and whether funding provided
financial incentives or disincentives for ESA use. Data from a
previous DOPPS III survey were also examined, which asked 295
Medical Director or Nurse Managers whether they identified drug
companies as being involved in the designing or writing of anemia
management protocols, and whether individuals received financial
reward for achieving anemia management performance targets.
Finally, publicly available policy statements were reviewed, members
of the governmental affairs sections from ESA manufacturers were
surveyed, and reviews of economic incentives in funding in the
DOPPS countries were examined.9,42–53
Statistical methods
ESA dose, hemoglobin levels, and patient characteristics were weighted
by the proportion of each facility’s patients participating in the study
using the SURVEY MEANS procedure in SAS. SURVEYREG and
SURVEYLOGISTIC were used to test demographic differences between
countries and the statistical significance of linear trends in mean values
across phases for each country in bivariate models. For each country, a
multivariable MIXED model tested associations between mean patient
ESA dose and phase, adjusting for the listed covariates and for clustering
by facility. The missing indicator approach included all patients even if
they had missing data. Only patients with non-missing data for a variable
contributed to its parameter estimate. The effect of iron dose on the
relationship between ESA dose and phase was tested in multivariable
MIXED models. Correlations of percent dose change and other variables
were calculated in linear regression models after aggregating to the
country level and calculating the percent change over various phases. For
analyses using medians, significance testing used the Wald and likelihood
ratio methods. A two-tailed statistical significance level of 0.05 was used.
Analyses were performed using SAS, version 9.1.
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